EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Efficacy and safety of Galgeun-tang-ga-cheongung-sinyi for nasal congestion with common cold: A study protocol for randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial

Seong-Cheon Woo, Yee Ran Lyu, Byong-Kab Kang, Bok-Nam Seo iD, Ae-Ran Kim, Boram Lee, Yang Chun Park iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0342433 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS One, 2026. Verfasst von Seong-Cheon Woo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Internal Medicine, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Common Cold, Drugs, Chinese Herbal, Nasal Obstruction. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Common cold is a common respiratory disease caused by a viral infection of the upper respiratory tract, leading to various symptoms including cough, sneezing, nasal congestion, and sore throat. As the medications used to treat the common cold may cause adverse effects such as gastrointestinal symptoms, drowsiness, and decreased concentration, it is necessary to explore alternative treatments for patients with the common cold. The aim of this study is to assess the effectiveness and safety of Galgeun-tang-ga-cheongung-sinyi (GGTCS), an herbal formula used to treat respiratory diseases, as an alternative medicine for nasal congestion with common cold.

Methods

This is a randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial. A total of 176 participants will be recruited and randomly allocated to the GGTCS group and control (placebo) group in a 1:1 allocation ratio. GGTCS or placebo will be administered three times per day for 7 days. The participants will be instructed to discontinue the medicine if the symptoms of the common cold disappear within 7 days of the treatment period and return the remaining medicine to the investigators. The primary outcome measures are changes in the total score of the Wisconsin Upper Respiratory Symptom Survey-21-Korean version (WURSS-21-K) (symptom score + quality of life score) on day 7 compared with baseline. Secondary outcome measures include the total, symptom, and quality of life scores of the WURSS-21-K, nasal congestion severity score, nasal and systemic symptom score visual analogue scale (VAS), duration of common cold symptoms, recovery from common cold, global evaluation of efficacy, and 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L). The exploratory outcome measure is a questionnaire for common cold pattern identification (QCCPI), and the safety assessment factors include adverse effects, vital signs, electrocardiograms, and clinical laboratory tests.

Discussion

The goal of this study is to assess the effectiveness and safety of GGTCS for nasal congestion with the common cold and the clinical use of herbal medicine. The results are expected to help researchers design further clinical trials using herbal medicines to treat the common cold.

Trial registration

This trial was registered on February 28, 2025 at the National Clinical Trial Registry Clinical Research Information Service ( https://cris.nih.go.kr ) with the identifier number KCT0010251.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Common ColdDrugs, Chinese HerbalNasal ObstructionHumansDouble-Blind MethodRandomized Controlled Trials as TopicMulticenter Studies as TopicFemaleMaleAdultTreatment OutcomeQuality of LifeMiddle AgedYoung Adult

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Department of Internal Medicine, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
  • KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
  • Clinical Medicine Division, R&D Strategy Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.

ORCID-Profile: Bok-Nam Seo, Yang Chun Park

Förderung

  • Ministry of Health and Welfare

Zitieren

APA

Woo, S. C., Lyu, Y. R., Kang, B. K., Seo, B. N., Kim, A. R., Lee, B., & Park, Y. C. (2026). Efficacy and safety of Galgeun-tang-ga-cheongung-sinyi for nasal congestion with common cold: A study protocol for randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial. PLOS One. https://doi.org/10.1371/journal.pone.0342433

Vancouver

Woo SC, Lyu YR, Kang BK, Seo BN, Kim AR, Lee B, et al. Efficacy and safety of Galgeun-tang-ga-cheongung-sinyi for nasal congestion with common cold: A study protocol for randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial. PLOS One. 2026. doi:10.1371/journal.pone.0342433

BibTeX
@article{Woo2026,
  author = {Woo, Seong-Cheon and Lyu, Yee Ran and Kang, Byong-Kab and Seo, Bok-Nam and Kim, Ae-Ran and Lee, Boram and Park, Yang Chun},
  title = {Efficacy and safety of Galgeun-tang-ga-cheongung-sinyi for nasal congestion with common cold: A study protocol for randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0342433}
}
Kostenlos starten →